Choksi Laboratories (BSE 526546)₹198.90−0.38%Healthcare Service Provider
In the Mar 2026 quarter (standalone), Choksi Laboratories reported sales of ₹12.86 Cr, up 12.5% from Mar 2025, and net profit of ₹1.02 Cr, up 12.1% year on year. For the year to Mar 2026, sales were ₹46.16 Cr and net profit ₹1.95 Cr.
Company filings, standalone accounts; latest reported quarter Mar 2026
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 8.90 | 7.97 | 8.81 | 11.15 | 10.78 | 9.28 | 10.41 | 11.43 | 11.28 | 11.15 | 10.85 | 12.86 |
| Expenses | 6.46 | 5.86 | 6.57 | 7.65 | 7.93 | 6.92 | 7.87 | 7.93 | 8.36 | 8.21 | 8.18 | 9.21 |
| Operating Profit | 2.42 | 2.12 | 2.23 | 3.48 | 2.82 | 2.35 | 2.53 | 3.49 | 2.89 | 2.92 | 2.65 | 3.63 |
| OPM % | 27.4% | 26.6% | 25.6% | 31.4% | 26.4% | 25.6% | 24.5% | 30.8% | 25.9% | 26.4% | 24.7% | 28.5% |
| Other Income | 0.00 | 0.04 | 0.00 | 0.05 | 0.00 | 0.00 | 0.00 | 0.03 | 0.00 | 0.00 | 0.88 | 0.05 |
| Interest | 0.81 | 0.73 | 0.66 | 0.76 | 0.71 | 0.65 | 0.68 | 0.57 | 0.59 | 0.68 | 0.80 | 0.70 |
| Depreciation | 1.40 | 1.42 | 1.44 | 1.50 | 1.51 | 1.62 | 1.69 | 1.71 | 1.69 | 1.70 | 1.84 | 1.90 |
| Profit before tax | 0.21 | 0.00 | 0.13 | 1.28 | 0.61 | 0.09 | 0.17 | 1.25 | 0.61 | 0.55 | 0.90 | 1.09 |
| Tax % | −59.1% | 0.0% | 57.2% | 46.5% | 30.7% | 20.1% | 44.5% | 27.0% | 38.7% | 57.2% | 64.9% | 6.4% |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.27 | 0.00 |
| Net Profit | 0.35 | 0.00 | 0.05 | 0.67 | 0.41 | 0.07 | 0.10 | 0.91 | 0.38 | 0.23 | 0.30 | 1.02 |
| EPS (Rs) | 0.53 | 0.02 | 0.10 | 0.99 | 0.61 | 0.12 | 0.17 | 1.33 | 0.57 | 0.35 | 0.46 | 1.49 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 25.15 | 28.72 | 30.47 | 33.84 | 28.22 | 25.74 | 30.10 | 34.55 | 36.80 | 41.90 | 46.16 | 46.14 |
| Expenses | 20.02 | 23.91 | 24.12 | 26.55 | 24.69 | 21.64 | 21.20 | 24.24 | 26.49 | 30.58 | 33.97 | 33.96 |
| Operating Profit | 5.14 | 4.77 | 6.33 | 7.25 | 3.55 | 4.11 | 8.89 | 10.26 | 10.27 | 11.29 | 12.12 | 12.09 |
| OPM % | 20.6% | 16.8% | 20.9% | 21.6% | 12.7% | 16.1% | 29.7% | 29.9% | 28.1% | 27.1% | 26.4% | 26.2% |
| Other Income | −0.04 | 0.85 | 0.34 | 0.24 | −2.79 | 0.48 | 0.11 | 2.46 | 0.15 | 0.06 | 0.96 | 0.93 |
| Interest | 1.22 | 1.46 | 1.58 | 1.53 | 1.88 | 2.81 | 3.22 | 3.51 | 3.05 | 2.71 | 2.81 | 2.77 |
| Depreciation | 2.74 | 2.87 | 3.17 | 3.69 | 4.57 | 4.61 | 5.44 | 5.51 | 5.72 | 6.51 | 7.10 | 7.13 |
| Profit before tax | 1.13 | 1.30 | 1.93 | 2.28 | −5.70 | −2.80 | 0.35 | 3.71 | 1.66 | 2.14 | 3.18 | 3.15 |
| Tax % | 36.9% | 32.1% | 29.9% | 30.1% | −32.0% | −7.1% | 44.5% | 13.8% | 33.0% | 29.4% | 38.6% | — |
| Exceptional items | −0.03 | 0.20 | 0.00 | 0.00 | −3.14 | 0.02 | 0.00 | 1.58 | 0.00 | 0.00 | 0.47 | 0.27 |
| Net Profit | 0.71 | 0.88 | 1.34 | 1.59 | −3.87 | −2.60 | 0.20 | 3.20 | 1.10 | 1.51 | 1.95 | 1.93 |
| EPS (Rs) | 1.04 | 1.29 | 1.95 | 2.31 | −5.58 | −3.76 | 0.31 | 4.62 | 1.60 | 2.19 | 2.82 | 2.87 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 6.96 | 6.96 | 6.96 | 6.95 | 6.95 | 6.96 | 6.94 | 6.94 | 6.94 | 6.95 | 6.94 | 6.95 |
| Reserves | 12.33 | 13.05 | 14.14 | 15.40 | 17.00 | 13.23 | 10.74 | 10.91 | 14.11 | 15.21 | 16.60 | 18.55 |
| Borrowings | 11.66 | 13.69 | 11.21 | 12.43 | 17.04 | 31.66 | 39.07 | 37.23 | 32.40 | 30.85 | 29.14 | 30.80 |
| Other Liabilities | 6.66 | 8.76 | 8.27 | 9.80 | 14.22 | 13.08 | 9.44 | 9.17 | 6.81 | 8.82 | 12.51 | 15.45 |
| Total Liabilities | 37.61 | 42.46 | 40.58 | 44.58 | 55.21 | 64.93 | 66.19 | 64.25 | 60.26 | 61.83 | 65.19 | 71.75 |
| Fixed Assets | 19.24 | 17.58 | 22.18 | 28.55 | 34.69 | 33.00 | 50.13 | 46.42 | 44.73 | 43.33 | 47.48 | 51.39 |
| CWIP | 2.72 | 9.00 | 4.27 | 0.00 | 3.24 | 13.07 | 0.51 | 1.66 | 0.32 | 2.98 | 0.00 | 0.41 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 15.65 | 15.88 | 14.13 | 16.03 | 17.28 | 18.86 | 15.55 | 16.17 | 15.21 | 15.52 | 17.71 | 19.95 |
| Inventories | 0.00 | 0.00 | 0.22 | 0.28 | 0.40 | 0.17 | 0.10 | 0.24 | 0.20 | 0.35 | 0.55 | 0.23 |
| Trade receivables | 8.43 | 8.55 | 8.77 | 9.85 | 8.76 | 6.96 | 8.14 | 10.26 | 10.61 | 10.36 | 11.22 | 14.68 |
| Cash & equivalents | 0.83 | 0.93 | 0.57 | 0.94 | 0.24 | 0.44 | 0.32 | 0.40 | 0.35 | 0.67 | 0.62 | 0.22 |
| Total Assets | 37.61 | 42.46 | 40.58 | 44.58 | 55.21 | 64.93 | 66.19 | 64.25 | 60.26 | 61.83 | 65.19 | 71.75 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | 2.31 | 0.02 | 6.59 | 6.27 | 6.93 | 2.88 | 5.92 | 7.91 | 8.27 | 11.60 | 11.82 | 7.88 |
| Cash from investing activity | −0.74 | −0.02 | −1.89 | −4.94 | −9.79 | −13.81 | −7.67 | −2.72 | −0.72 | −6.67 | −7.64 | −7.09 |
| Cash from financing activity | −1.38 | 0.00 | −4.91 | −0.95 | 2.14 | 11.13 | 1.64 | −5.09 | −7.64 | −4.60 | −4.23 | −1.21 |
| Net cash flow | 0.22 | 0.00 | −0.21 | 0.40 | −0.73 | 0.21 | −0.13 | 0.11 | −0.08 | 0.33 | −0.05 | −0.42 |
| Capex | 0.67 | 0.00 | 3.25 | 4.96 | 6.79 | 1.50 | 7.61 | 1.18 | 4.14 | 4.45 | 7.71 | 7.80 |
| Free cash flow | 1.39 | 0.00 | 4.17 | 1.29 | −3.08 | −11.17 | −2.17 | 5.04 | 7.32 | 4.53 | 4.08 | 0.61 |
| CFO / OP % | 53.1% | 0.0% | 124.1% | 124.1% | 137.1% | 111.1% | 68.1% | 75.1% | 73.1% | 117.1% | 122.1% | 69.1% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor days | 126 | 125 | 112 | 119 | 95 | 91 | 116 | 125 | 113 | 103 | 98 | 117 |
| Inventory days | 0 | 0 | 29 | 32 | 39 | 21 | 17 | 47 | 36 | 52 | 67 | 26 |
| Days payable | — | — | 591 | 594 | 661 | 723 | 686 | 741 | 297 | 560 | 639 | 594 |
| Cash conversion cycle | 125 | 124 | −452 | −446 | −529 | −613 | −555 | −571 | −151 | −407 | −476 | −453 |
| Working capital days | 30 | 4 | −23 | −17 | 29 | 22 | −49 | −22 | 13 | −48 | −70 | −34 |
| ROCE % | 8.0% | 7.6% | 7.4% | 10.6% | 10.1% | −1.5% | 0.0% | 6.4% | 9.2% | 8.9% | 9.2% | 9.7% |
For the Mar 2026 quarter, Choksi Laboratories reported sales of ₹12.86 Cr, up 12.5% year on year and net profit of ₹1.02 Cr, up 12.1% year on year. The operating margin was 28.5%.
Choksi Laboratories' sales for the year to Mar 2026 were ₹46.16 Cr; over the last twelve months they were ₹46.14 Cr.
Net profit for the year to Mar 2026 was ₹1.95 Cr, and ₹1.93 Cr over the last twelve months. Earnings per share over the same trailing period were ₹2.87.
Choksi Laboratories reported borrowings of ₹30.80 Cr at Mar 2026, against cash and equivalents of ₹0.22 Cr.
Cash from operations was ₹7.88 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹0.61 Cr.